Updated Monday, 4/27. A handful of IPOs are currently scheduled for the week ahead, joined by Bill Ackman’s Pershing Square deals. Some smaller issuers may also join the calendar throughout the week. Neuropsychiatric therapeutics biotech ...read more
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. ...read more
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Canadian royalty acquirer The Metals Royalty Co. (TMCR) completed its direct listing on the Nasdaq and opened for trading at $15, where it commanded a market cap of...read more
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, filed on Wednesday with the SEC for an initial public offering. The company used a placeholder of $100 million for its proposed deal size. Avalyn Pharma is a...read more
US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut
Updated Monday, 4/27. A handful of IPOs are currently scheduled for the week ahead, joined by Bill Ackman’s Pershing Square deals. Some smaller issuers may also join the calendar throughout the week. Neuropsychiatric therapeutics biotech ...read more
Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. ...read more
US IPO Weekly Recap: Pipeline swells with sizable IPO filings as Metals Royalty direct lists
One IPO priced this past week, joined by two SPACs, and twelve deals joined the pipeline. Canadian royalty acquirer The Metals Royalty Co. (TMCR) completed its direct listing on the Nasdaq and opened for trading at $15, where it commanded a market cap of...read more
Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, filed on Wednesday with the SEC for an initial public offering. The company used a placeholder of $100 million for its proposed deal size. Avalyn Pharma is a...read more